A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia
The purpose of this study is to evaluate the efficacy and safety of enclitide chloride, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of enclitide chloride tested in this study is superior to placebo on percent change from baseline in LDL-C at Week 8.
Inclusion Criteria:
Exclusion Criteria:
Beverly Hills, California 90211, United States
Santa Ana, California 92704, United States
Jackson, Mississippi 39216, United States
Albuquerque, New Mexico 87106, United States
Houston, Texas 77030, United States
Kuse-gun Kumiyama-cho, Kyoto 613-0034, Japan
Suita-shi, Osaka 565-0853, Japan
Adachi-ku, Tokyo 123-0845, Japan
Chiyoda-ku, Tokyo 101-0041, Japan
Shinjuku-ku, Tokyo 160-0008, Japan
Toshimaku, Tokyo 171-0014, Japan
Guadalajara, Jalisco 04460, Mexico
Guadalajara, Jalisco 44150, Mexico
Mexico City, Mexico City 14080, Mexico
Ciudad Madero, Tamaulipas 89440, Mexico
Lørenskog, Akershus 1478, Norway
Bornova, İzmir 35100, Turkey (Türkiye)
Glasgow, Glasgow City G51 4TF, United Kingdom
West Midlands, Walsall WS2 9PS, United Kingdom